Table 5.
Clinical and microbiologic outcomes among patients with baseline ESBL-producing Escherichia coli characteristics (occurrence of primary and secondary endpoints) a .
| Endpoints | PTZ (n = 37) | Meropenem (n = 12) | Total (n = 49) | p-value |
|---|---|---|---|---|
| Primary efficacy endpoints | ||||
| Success | 27 (73%) | 9 (75%) | 36 (73.5%) | 0.890 |
| Failure | 3 (8.1%) | 1 (8.3%) | 4 (8.2%) | |
| Indeterminate | 7 (18.9%) | 2 (16.7%) | 9 (18.4%) | |
| Secondary efficacy endpoint—clinical endpoint response | ||||
| Success | 19 (51.4%) | 3 (25%) | 22 (44.9%) | 0.066 |
| Failure | 6 (16.2%) | 3 (25%) | 9 (18.4%) | |
| Indeterminate | 12 (32.4%) | 6 (50%) | 18 (36.7%) | |
| Secondary efficacy endpoint—microbiological endpoint response | ||||
| Success | 22 (59.5%) | 4 (33.3%) | 26 (53.1%) | 0.115 |
| Failure | 6 (16.2%) | 1 (8.3%) | 7 (12.3%) | |
| Indeterminate | 9 (24.3%) | 7 (58.3%) | 16 (32.7%) | |
a
Data are expressed as No. (%) of participants unless otherwise indicated.